Developer docs
API playgroundTry for free, no card

Search company profiles

Eurofins Discovery

Full company profile

uuid000afah

Namestring
Eurofins Discovery
Company typeenum
Private
Founded yearint
1987
Descriptiontext

Eurofins Discovery is a global contract research organization (CRO) that provides drug discovery and safety pharmacology services to pharmaceutical and biotechnology clients. Its core offerings span the preclinical pipeline, including comprehensive drug discovery services, safety assessment of drug candidates, and translational biology support, sold primarily through enterprise field sales on a project-based, quote-priced engagement model. The company is positioned as a horizontal services provider serving the broader pharma and biotech R&D segment rather than a vertical specialist in any single therapeutic area.

The company's underlying scientific stack centers on human-tissue-based assay development and safety pharmacology. In July 2022 Eurofins Discovery acquired DiscoveryBioMed, a CRO specializing in human bioassays developed from both diseased and normal human tissues, which added translational biology capabilities that are differentiated relative to standard preclinical CRO offerings. In April 2023 the company acquired Calixar for an undisclosed amount, further extending the service portfolio. Together, these acquisitions indicate a roll-up strategy focused on bolting on specialized scientific capabilities that complement the core drug discovery and safety pharmacology franchise.

Eurofins Discovery operates as a service line within Eurofins Scientific, a larger European testing and analytical services group, which provides global geographic reach and back-office scale. Revenue mechanics are professional services–driven, with project-based contracts and pricing not publicly disclosed. Headcount is reported in the 501–1,000 range, with primary operational sites documented at St. Charles (United States) and Birmingham, Alabama (inherited from DiscoveryBioMed). Customer logos are not publicly disclosed, and the segment approach is horizontal across pharmaceutical and biotechnology R&D buyers.

Short descriptiontext

Eurofins Discovery is a global contract research organization providing drug discovery, safety pharmacology, and translational biology services—including specialized human bioassay development—to pharmaceutical and biotechnology companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSt. Charles, United States
HQ citystring
St. Charles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery services, safety pharmacology, contract research organization, human bioassays, translational biology
Industry3 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery & Contract Research Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Organization (CRO) Services
TypeProfessional Services
Description

Eurofins Discovery generates revenue through providing drug discovery and safety pharmacology services as a contract research organization to pharmaceutical and biotechnology companies. Services include developing human bioassays, translational biology support, and comprehensive drug discovery solutions.

prnewswire.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Eurofins Discovery is a global contract research organization (CRO) providing drug discovery and safety pharmacology services to pharmaceutical and biotechnology companies. Its portfolio spans target identification through preclinical testing, including human bioassay development from diseased and normal human tissues, translational biology support, and safety assessment of drug candidates. The portfolio has been expanded through acquisitions such as DiscoveryBioMed (human tissue-based bioassays) and Calixar.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Eurofins Discovery operates as a global provider of drug discovery services, consisting of core service offerings including safety pharmacology services and human bioassay development. The portfolio was expanded through the acquisition of DiscoveryBioMed, which specializes in human bioassays from diseased and normal human tissues, enhancing translational biology capabilities for R&D support.

Product and service3 records
1Drug Discovery Services
CategoryDrug Discovery Services
2Safety Pharmacology Services
CategorySafety Pharmacology
3DiscoveryBioMed Human Bioassays
CategoryHuman Bioassays / Translational Biology
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1DiscoveryBioMed
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-07-05
Description

Eurofins Discovery acquired DiscoveryBioMed, a CRO specializing in developing human bioassays from diseased and normal human tissues. The acquisition enhances Eurofins Discovery's portfolio of drug discovery services and supports translational biology for R&D. DiscoveryBioMed brings specialized capabilities in human tissue-based bioassays that complement Eurofins' existing drug discovery and safety pharmacology service offerings.

prnewswire.com
Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

India-based CRO offering drug discovery, medicinal chemistry, DMPK, and safety services. An emerging competitor in mid-tier discovery outsourcing that overlaps with Eurofins Discovery's core offering.

TypeDirect peer
Description

Germany-based drug discovery CRO and integrated R&D platform offering target identification, hit discovery, and translational biology. Closely comparable to Eurofins Discovery's discovery-plus-translational positioning.

TypeBroad incumbent
Description

Through its PPD acquisition, Thermo Fisher offers integrated discovery, preclinical, and clinical CRO services. A broad incumbent that competes for the same large-pharma discovery outsourcing engagements.

TypeDirect peer
Description

China-based contract research organization with extensive drug discovery and preclinical safety pharmacology offerings. Competes head-to-head with Eurofins Discovery for global pharma/biotech discovery outsourcing dollars.

TypeBroad incumbent
Description

Global life sciences services giant with discovery, preclinical, and clinical CRO capabilities. Larger and broader than Eurofins Discovery, but competes in the same outsourced drug discovery market.

TypeRegional player
Description

Clinical and preclinical CRO with strong North American presence serving pharma/biotech. Competes for overlapping preclinical and translational work, though its historical emphasis has been more clinical-stage than pure discovery.

TypeDirect peer
Description

Large CRO providing drug discovery, preclinical, and clinical development services. Overlaps with Eurofins Discovery in preclinical and safety pharmacology work, serving the same pharma/biotech customer base.

TypeDirect peer
Description

Global preclinical CRO offering discovery, safety pharmacology, and DMPK services to pharma and biotech. Directly comparable to Eurofins Discovery across the early-stage drug discovery workflow, with a much larger commercial footprint.

TypeBroad incumbent
Description

Parent organization and global testing services conglomerate within which Eurofins Discovery operates. Provides shared infrastructure, client relationships, and capital that fundamentally shape the division's positioning.

TypeDirect peer
Description

China-headquartered CRO offering drug discovery, DMPK, safety pharmacology, and translational services. Comparable scale and service mix to Eurofins Discovery, increasingly winning global discovery outsourcing mandates.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eurofins Discovery

Drug Discovery & Contract Research Serviceseurofinsdiscoveryservices.com

Eurofins Discovery is a global contract research organization providing drug discovery, safety pharmacology, and translational biology services—including specialized human bioassay development—to pharmaceutical and biotechnology companies.

What Eurofins Discovery does

Eurofins Discovery is a global contract research organization (CRO) that provides drug discovery and safety pharmacology services to pharmaceutical and biotechnology clients. Its core offerings span the preclinical pipeline, including comprehensive drug discovery services, safety assessment of drug candidates, and translational biology support, sold primarily through enterprise field sales on a project-based, quote-priced engagement model. The company is positioned as a horizontal services provider serving the broader pharma and biotech R&D segment rather than a vertical specialist in any single therapeutic area.

The company's underlying scientific stack centers on human-tissue-based assay development and safety pharmacology. In July 2022 Eurofins Discovery acquired DiscoveryBioMed, a CRO specializing in human bioassays developed from both diseased and normal human tissues, which added translational biology capabilities that are differentiated relative to standard preclinical CRO offerings. In April 2023 the company acquired Calixar for an undisclosed amount, further extending the service portfolio. Together, these acquisitions indicate a roll-up strategy focused on bolting on specialized scientific capabilities that complement the core drug discovery and safety pharmacology franchise.

Eurofins Discovery operates as a service line within Eurofins Scientific, a larger European testing and analytical services group, which provides global geographic reach and back-office scale. Revenue mechanics are professional services–driven, with project-based contracts and pricing not publicly disclosed. Headcount is reported in the 501–1,000 range, with primary operational sites documented at St. Charles (United States) and Birmingham, Alabama (inherited from DiscoveryBioMed). Customer logos are not publicly disclosed, and the segment approach is horizontal across pharmaceutical and biotechnology R&D buyers.

Eurofins Discovery firmographics

Firmographics
Name
Eurofins Discovery
Website
https://eurofinsdiscoveryservices.com
Company type
Private
Founded year
1987
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Eurofins Discovery is a global contract research organization providing drug discovery, safety pharmacology, and translational biology services—including specialized human bioassay development—to pharmaceutical and biotechnology companies.
Ownership category
akta.pro rank

Eurofins Discovery industry classification

Industry
Product category
Drug Discovery & Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Drug discovery services
  • Safety pharmacology
  • Contract research organization
  • Human bioassays
  • Translational biology

Where Eurofins Discovery is headquartered

Location

Headquarters

HQ city
St. Charles
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Eurofins Discovery business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Research Organization (CRO) Services: Eurofins Discovery generates revenue through providing drug discovery and safety pharmacology services as a contract research organization to pharmaceutical and biotechnology companies. Services include developing human bioassays, translational biology support, and comprehensive drug discovery solutions.

Go-to-market motion1 record

Distribution channels1 record

Eurofins Discovery product offering

Product offering

Core offering

Eurofins Discovery is a global contract research organization (CRO) providing drug discovery and safety pharmacology services to pharmaceutical and biotechnology companies. Its portfolio spans target identification through preclinical testing, including human bioassay development from diseased and normal human tissues, translational biology support, and safety assessment of drug candidates. The portfolio has been expanded through acquisitions such as DiscoveryBioMed (human tissue-based bioassays) and Calixar.

Product overview

Eurofins Discovery operates as a global provider of drug discovery services, consisting of core service offerings including safety pharmacology services and human bioassay development. The portfolio was expanded through the acquisition of DiscoveryBioMed, which specializes in human bioassays from diseased and normal human tissues, enhancing translational biology capabilities for R&D support.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug Discovery Services
  • Safety Pharmacology Services
  • DiscoveryBioMed Human Bioassays

Companies that use Eurofins Discovery

Customer profile

Segments1 record

Ideal customer profiles1 record

Eurofins Discovery technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Eurofins Discovery partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • DiscoveryBioMedcoreStrategic or Co-development Partner · 5 July 2022Eurofins Discovery acquired DiscoveryBioMed, a CRO specializing in developing human bioassays from diseased and normal human tissues. The acquisition enhances Eurofins Discovery's portfolio of drug discovery services and supports translational biology for R&D. DiscoveryBioMed brings specialized capabilities in human tissue-based bioassays that complement Eurofins' existing drug discovery and safety pharmacology service offerings.

Scale indicators3 records

Recent moves2 records

Expansion highlights3 records

Eurofins Discovery competitors and assessment

Company assessment

Emerging players

  • Sai Life Sciences: India-based CRO offering drug discovery, medicinal chemistry, DMPK, and safety services. An emerging competitor in mid-tier discovery outsourcing that overlaps with Eurofins Discovery's core offering.

Direct peers

  • Evotec: Germany-based drug discovery CRO and integrated R&D platform offering target identification, hit discovery, and translational biology. Closely comparable to Eurofins Discovery's discovery-plus-translational positioning.
  • WuXi AppTec: China-based contract research organization with extensive drug discovery and preclinical safety pharmacology offerings. Competes head-to-head with Eurofins Discovery for global pharma/biotech discovery outsourcing dollars.
  • Labcorp Drug Development (formerly Covance): Large CRO providing drug discovery, preclinical, and clinical development services. Overlaps with Eurofins Discovery in preclinical and safety pharmacology work, serving the same pharma/biotech customer base.
  • Charles River Laboratories: Global preclinical CRO offering discovery, safety pharmacology, and DMPK services to pharma and biotech. Directly comparable to Eurofins Discovery across the early-stage drug discovery workflow, with a much larger commercial footprint.
  • Pharmaron: China-headquartered CRO offering drug discovery, DMPK, safety pharmacology, and translational services. Comparable scale and service mix to Eurofins Discovery, increasingly winning global discovery outsourcing mandates.

Broad incumbents

  • Thermo Fisher Scientific (PPD): Through its PPD acquisition, Thermo Fisher offers integrated discovery, preclinical, and clinical CRO services. A broad incumbent that competes for the same large-pharma discovery outsourcing engagements.
  • IQVIA: Global life sciences services giant with discovery, preclinical, and clinical CRO capabilities. Larger and broader than Eurofins Discovery, but competes in the same outsourced drug discovery market.
  • Eurofins Scientific: Parent organization and global testing services conglomerate within which Eurofins Discovery operates. Provides shared infrastructure, client relationships, and capital that fundamentally shape the division's positioning.

Regional players

  • Syneos Health: Clinical and preclinical CRO with strong North American presence serving pharma/biotech. Competes for overlapping preclinical and translational work, though its historical emphasis has been more clinical-stage than pure discovery.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Eurofins Discovery financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eurofins Discovery leadership team

Management profile

Number of profiles

Eurofins Discovery subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Eurofins Discovery funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eurofins Discovery M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eurofins Discovery

What does Eurofins Discovery do?

Eurofins Discovery is a global contract research organization (CRO) providing drug discovery and safety pharmacology services to pharmaceutical and biotechnology companies. Its portfolio spans target identification through preclinical testing, including human bioassay development from diseased and normal human tissues, translational biology support, and safety assessment of drug candidates. The portfolio has been expanded through acquisitions such as DiscoveryBioMed (human tissue-based bioassays) and Calixar.

Is Eurofins Discovery a public or private company?

Eurofins Discovery is a private company. It is classified as corporate owned and is currently operating.

When was Eurofins Discovery founded?

Eurofins Discovery was founded in 1987. It employs 501 to 1,000 people.

Where is Eurofins Discovery based?

Eurofins Discovery is headquartered in St. Charles, United States, in the North America region.

How does Eurofins Discovery make money?

One revenue line is on record: contract Research Organization (CRO) Services.

Who are Eurofins Discovery's main competitors?

Sai Life Sciences is listed as an emerging player. Direct peers are Evotec, WuXi AppTec, Labcorp Drug Development (formerly Covance), Charles River Laboratories and Pharmaron. Broad incumbents are Thermo Fisher Scientific (PPD), IQVIA and Eurofins Scientific. Syneos Health is listed as a regional player.

Does Eurofins Discovery have an API?

No public API is recorded for Eurofins Discovery.

What industry is Eurofins Discovery in?

Eurofins Discovery's product category is Drug Discovery & Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAC, Toxicology & Safety Assessment CROs (GLP). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsADC Developmentfrom Concept to ClinicEurofins Discovery offers a fully integrated ADC development platform covering linker-payload design, bioconjugation, purification, DAR analysis, and functional assays. The company aims to mitigate development risks and shorten timelines while optimizing ADC safety, efficacy, and manufacturability.EIN PresswireADC Developmentfrom Concept to ClinicEurofins Discovery offers a fully integrated ADC development platform covering linker-payload design, bioconjugation, purification, DAR analysis, and functional assays. The company aims to mitigate development risks and shorten timelines while optimizing ADC safety, efficacy, and manufacturability.News-MedicalDr. GPCR and Eurofins Discovery join forces to advance GPCR drug discoveryDr. GPCR and Eurofins Discovery announced a strategic partnership to advance GPCR drug discovery. Eurofins Discovery offers end-to-end services including compound profiling, deorphanization, and over 2,750 assays across therapeutic areas. The collaboration aims to accelerate GPCR-targeted therapeutics through integrated services and community engagement.TmcnetEurofins Discovery Extends AI-powered Integrated Drug Discovery CollaborationEurofins Discovery renewed its collaboration with Dompé farmaceutici S.p.A. for a second year, combining Eurofins' DiscoveryOne capabilities with Dompé's Exscalate AI platform. The partnership aims to accelerate novel therapeutics through virtual screening of trillions of molecules. The collaboration supports Dompé's multi-target program and benefits researchers using internal AI platforms.MorningstarEurofins Discovery Extends AI-powered Integrated Drug Discovery CollaborationEurofins Discovery renewed its collaboration with Dompé farmaceutici for a second year, combining Eurofins' DiscoveryOne capabilities with Dompé's Exscalate AI platform. The partnership aims to accelerate novel therapeutics through virtual screening of trillions of molecules. Eurofins Discovery's portfolio includes over 12,000 off-the-shelf assays.Business Wire BlogEurofins Discovery Extends AI-powered Integrated Drug Discovery CollaborationEurofins Discovery renewed its collaboration with Dompé farmaceutici S.p.A. for a second year, combining Eurofins' Integrated Drug Discovery capabilities with Dompé's Exscalate AI platform. The partnership aims to accelerate novel therapeutics through virtual screening of trillions of molecules.MorningstarEurofins Discovery Introduces Innovative DiscoveryAI SAFIRE: A New AI-Driven Platform for Drug Discovery Trained Using Proprietary DatasetsEurofins Discovery launched DiscoveryAI SAFIRE, an AI-driven platform for predicting ADMET properties of molecules. The platform uses proprietary BioPrint data and public datasets, achieving Matthews Correlation Coefficient values above 0.4 and accuracies over 80%. It is now available for customer use through the company's website.MorningstarEurofins Discovery Introduces Innovative DiscoveryAI SAFIRE: A New AI-Driven Platform for Drug Discovery Trained Using Proprietary DatasetsEurofins Discovery launched DiscoveryAI SAFIRE, an AI-driven platform for predicting ADMET properties of molecules. The platform uses proprietary BioPrint database data and public datasets, achieving Matthews Correlation Coefficient values above 0.4 and accuracies over 80%. It is available for customer use through the Eurofins Discovery website.YahooEurofins Discovery Introduces Innovative DiscoveryAI SAFIRE: A New AI-Driven Platform for Drug Discovery Trained Using Proprietary DatasetsEurofins Discovery launched DiscoveryAI SAFIRE, an AI-driven platform for predicting ADMET properties of molecules, trained on its proprietary BioPrint database. The platform achieved Matthews Correlation Coefficient values above 0.4 and accuracies above 80% in a published study. It is now available for customer use through the Eurofins Discovery website.YahooEurofins Discovery Introduces Innovative DiscoveryAI SAFIRE: A New AI-Driven Platform for Drug Discovery Trained Using Proprietary DatasetsEurofins Discovery launched DiscoveryAI SAFIRE, an AI-driven platform for predicting ADMET properties of molecules. The platform uses proprietary BioPrint database data and public datasets, achieving Matthews Correlation Coefficient values above 0.4 and accuracies over 80%. It is available for customer use through the company's website.